Balance Sheet Components (Tables)

3 Months Ended

Mar. 31, 2025

Balance Sheet Related Disclosures [Abstract]

Schedule of Inventory

Inventory consisted of the following:


		March 31,				December 31,
(in thousands)		2025				2024
Raw materials		$	10,619			$	11,113
Work-in-process			27,425				20,529
Finished goods			3,435				2,083
Total inventory		$	41,479			$	33,725

Schedule of Other Accrued Liabilities

Other accrued liabilities consisted of the following:


		March 31,				December 31,
(in thousands)		2025				2024
Accrued contract manufacturing expenses		$	1,294			$	1,071
Accrued clinical and research expenses			326				611
Accrued professional services			4,291				8,682
Current portion of lease liabilities			1,280				1,572
Royalty obligation payable			3,336				2,951
Current portion of deferred royalty obligations			6,860				6,438
Accrued license fees and royalties			1,483				1,727
Other(1)			11,794				6,947
Total other accrued liabilities		$	30,664			$	29,999

(1) Amount as of March 31, 2025 and December 31, 2024 includes $8.6 million and $5.3 million advance payments received from our partner for inventory supply as discussed in Note 4, “License and Collaboration Arrangements”.

Schedule of Other Long-term Liabilities

Other long-term liabilities consisted of the following:


		March 31,				December 31,
(in thousands)		2025				2024
Long-term portion of deferred royalty obligation		$	60,918			$	63,096
Long-term portion of lease liabilities			1,091				1,179
Total other long-term liabilities		$	62,009			$	64,275